HomeVideoRyzodeg® Offers Improved Glycaemic Control

Ryzodeg® Offers Improved Glycaemic Control

Data presented today at the World Diabetes Congress of the International Diabetes Federation (IDF) show that adults with type 2 diabetes achieved improved glycaemic control, significantly lower rates of overall and nocturnal confirmed hypoglycaemia for the full trial period, and a significantly lower rate of severe hypoglycaemia during the maintenance period (defined as week 16 onwards) with Ryzodeg® compared to biphasic insulin aspart 30, both administered twice-daily1.

Ryzodeg® is the first combination of two distinct insulin analogues, Tresiba® (insulin degludec), the once-daily basal insulin with an ultra-long duration of action, and the well-established mealtime insulin NovoRapid® (insulin aspart), in the ratio of 70% and 30%, in one pen for people with type 2 diabetes2-4.

To view the Multimedia News Release, go to http://www.multivu.com/mnr/64158-ryzodeg-improved-glycaemic-control

Likes: 0

Viewed: 91


Previous post
What Is a Normal Blood Sugar Level?/Treatment of Type 1 Diabetes/Austintown/National Diabetes Statis
Next post
Type 2 Diabetes - The Effect of High Thyroid-Stimulating Hormones on Small Blood Vessels

Leave a Reply

Be the First to Comment!

Notify of